Kinevant Sciences GmbH Report issue

For profit Phase 2
Founded: Basle-City Switzerland (2018)
Status: Acquired by Roivant Sciences, Inc. (2018) → now Sumitomo Dainippon (2005)

Organization Overview

First Clinical Trial
2019
NCT04205851
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Kinevant Sciences | Kinevant Sciences GmbH

Active Ingredients

Drugs in Phase 2 Trials (2)

gimsilumab (2 trials)

namilumab (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Collagen Diseases (Phase 1)

Inflammation (Phase 1)

Lung Injury (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Rheumatic Diseases (Phase 1)

Spondylitis (Phase 1)

Spondylitis, Ankylosing (Phase 1)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2